Zingerenko B V, Makarova N P, Kokoeva D N, Kosenko M G, Sorokina L E, Kalinina E A, Krasny A M
National Medical Research Center of Obstetrics, Gynecology, and Perinatology Named after Academician V. I. Kulakov, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2025 May;179(1):123-126. doi: 10.1007/s10517-025-06445-4. Epub 2025 Jul 19.
We compared the content of extracellular genomic and mitochondrial DNA (ec-gDNA and ec-mtDNA) in the follicular fluid (FF) of women after using two types of triggers for final oocyte maturation: human chorionic gonadotropin (hCG) and gonadotropin-releasing hormone agonist (GnRHa). The study included 43 women aged 21-35 years with preserved ovarian reserve according to hormonal profile and ultrasound examination, who were divided into two groups depending on the type of trigger: hCG at a dose of 10,000 IU (group 1; n = 30) and GnRHa at a dose of 0.2 mg (group 2; n = 13). From each patient, a sample of FF was obtained during transvaginal puncture from a dominant follicle without blood admixture. The content of ec-gDNA and ec-mtDNA was measured by qPCR. At the first stage, a positive correlation was found between the content of ec-gDNA and ec-mtDNA and the level of anti-Müllerian hormone, as well as between the level of ec-mtDNA and the number of oocytes. In patients reveiving GnRHa, the level of ec-mtDNA was significantly higher. There were no significant differences between the groups in the level of free ec-gDNA. The identified differences in ec-mtDNA in FF not only indicate different mechanisms of action of the used drugs, but also offer hope for the development of more precise approaches to the use of FF at the embryological stage of ART infertility treatment programs.
我们比较了使用两种终末卵母细胞成熟触发剂后的女性卵泡液(FF)中细胞外基因组DNA和线粒体DNA(ec-gDNA和ec-mtDNA)的含量,这两种触发剂分别是人绒毛膜促性腺激素(hCG)和促性腺激素释放激素激动剂(GnRHa)。该研究纳入了43名年龄在21 - 35岁之间、根据激素水平和超声检查卵巢储备功能正常的女性,她们根据触发剂类型分为两组:10000 IU剂量的hCG组(第1组;n = 30)和0.2 mg剂量的GnRHa组(第2组;n = 13)。从每位患者经阴道穿刺优势卵泡获取无血液混入的FF样本。通过qPCR测量ec-gDNA和ec-mtDNA的含量。在第一阶段,发现ec-gDNA和ec-mtDNA的含量与抗苗勒管激素水平之间存在正相关,以及ec-mtDNA水平与卵母细胞数量之间存在正相关。在接受GnRHa的患者中,ec-mtDNA水平显著更高。两组间游离ec-gDNA水平无显著差异。FF中ec-mtDNA的差异不仅表明所用药物的作用机制不同,也为在辅助生殖技术不孕治疗方案的胚胎学阶段更精确地使用FF提供了希望。